<DOC>
	<DOCNO>NCT01749111</DOCNO>
	<brief_summary>The purpose study determine whether cyclophosphamide post bone marrow transplant increase rate patient alive , remission without immunosuppression , one year transplant , compare combination methotrexate calcineurin inhibitor</brief_summary>
	<brief_title>Comparison Between Cyclophosphamide Combination Methotrexate + Calcineurin Inhibitor GVHD Prophylaxis</brief_title>
	<detailed_description>We propose study 150 patient receive graft versus host disease prophylaxis cyclophosphamide 50 mg/kg day +3 day +4 bone marrow transplantation , 150 patient receive usual combination methotrexate calcineurin inhibitor . The study design last 4 year . The primary endpoint rate patient alive , remission without immunosuppression , one year transplant . The assignment arm study do simple randomization .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Man woman 18 60 year age . The patient HLA match donor The patient must need bone marrow transplant malignant disease ( Acute leukemia , myelodysplastic syndrome , myeloproliferative disease myelodysplastic/myeloproliferative disease ) Patients want participate study , able give inform consent . Previous auto allogeneic hematopoietic stem cell transplant Performance Status &gt; 2 ( ECOG ) . Pregnancy HIV positive Active Infection Cardiac disease ejection fraction &lt; 45 % Lung disease FEV1 , FVC ou DLCO &lt; 50 % predicted value . Renal Insufficiency creatinine clearance &lt; 60 ml/minute . Liver disease bilirubin level &gt; twice reference value ALT AST &gt; three time normal reference .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>bone marrow transplantation</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>Acute lymphoid leukemia</keyword>
	<keyword>Myeloproliferative disease</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
</DOC>